SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Storey Robert F.)
 

Search: WFRF:(Storey Robert F.) > (2010-2014) > (2013) > Linköping University > Health-Related Qual...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Health-Related Quality of Life of Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes-Results from the PLATO Trial

Levin, Lars-Åke (author)
Linköpings universitet,Avdelningen för hälso- och sjukvårdsanalys,Hälsouniversitetet
Wallentin, Lars (author)
Uppsala universitet,Uppsala kliniska forskningscentrum (UCR),Uppsala University, Sweden
Bernfort, Lars (author)
Linköpings universitet,Avdelningen för hälso- och sjukvårdsanalys,Hälsouniversitetet
show more...
Andersson, David (author)
Linköpings universitet,Institutionen för medicin och hälsa,Hälsouniversitetet
Storey, Robert F. (author)
University of Sheffield, England
Bergstrom, Gina (author)
AstraZeneca RandD, Sweden
Lamm, Carl-Johan (author)
AstraZeneca RandD, Sweden
Janzon, Magnus (author)
Östergötlands Läns Landsting,Linköpings universitet,Kardiologi,Hälsouniversitetet,Kardiologiska kliniken US
Kaul, Padma (author)
University of Alberta, Canada
show less...
 (creator_code:org_t)
Wiley-Blackwell: No OnlineOpen / Elsevier, 2013
2013
English.
In: Value in Health. - : Wiley-Blackwell: No OnlineOpen / Elsevier. - 1098-3015 .- 1524-4733. ; 16:4, s. 574-580
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • Objectives: The purpose of this study was to compare the effects of ticagrelor versus clopidogrel on health-related quality of life in the PLATelet inhibition and patient Outcomes (PLATO) trial. Background: The PLATO trial showed that ticagrelor was superior to clopidogrel for the prevention of cardiovascular death, myocardial infarction, or stroke in a broad population of patients with acute coronary syndromes. Methods: HRQOL in the PLATO study was measured at hospital discharge, 6-month visit, and end of treatment (anticipated at 12 months) by using the EuroQol five-dimensional (EQ-5D) questionnaire. All patients who had an EQ-5D questionnaire assessment at discharge from the index hospitalization (n = 15,212) were included in the study. Patients who died prior to the end-of-treatment visit were assigned an EQ-5D questionnaire value of 0. Results: The EQ-5D questionnaire value at discharge among 7631 patients assigned to ticagrelor was 0.847 and among 7581 patients assigned to clopidogrel was 0.846 (P = 0.71). At 12 months, the mean EQ-5D questionnaire value was 0.840 for ticagrelor and 0.832 for clopidogrel (P = 0.046). Excluding patients who died resulted in mean EQ-5D questionnaire values of 0.864 among ticagrelor patients and 0.863 among clopidogrel patients (P = 0.69). Conclusions: In patients hospitalized with acute coronary syndromes with or without ST-segment elevation, treatment with ticagrelor was associated with a lower mortality but otherwise no difference in quality of life relative to treatment with clopidogrel. The improved survival and reduction in cardiovascular events with ticagrelor are therefore obtained with no loss in quality of life.

Keyword

acute coronary syndrome
clopidogrel
quality of life
ticagrelor
MEDICINE
MEDICIN

Publication and Content Type

ref (subject category)
art (subject category)

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view